The concept of immune surveillance against tumors. The first theories

Oncotarget

Volumn 8, Issue 4, 2017, Pages 7175-7180

  Ribatti, Domenico ^a,b  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Antigen; History of medicine; Immune surveillance; T cell; Tumor

Indexed keywords

ANTIBODY; GAMMA INTERFERON; IPILIMUMAB; PERFORIN; PROGRAMMED DEATH LIGAND 1 ANTIBODY; PROGRAMMED DEATH RECEPTOR 1 ANTIBODY; SIPULEUCEL T; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; BACTERIAL INFECTION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL INTERACTION; CELL KILLING; CELL THERAPY; DISEASE ASSOCIATION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOEDITING; IMMUNOLOGICAL PROCEDURES; IMMUNOMODULATION; IMMUNOSURVEILLANCE; LYMPHOCYTE; METASTATIC MELANOMA; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; THEORY; TUMOR CELL; TUMOR ESCAPE; TUMOR IMMUNITY; ANIMAL; HISTORY; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; IMMUNOTHERAPY; INCIDENCE; MOUSE; NEOPLASM;

ANIMALS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; INCIDENCE; MICE; NEOPLASMS; TUMOR ESCAPE;

EID: 85010767471     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12739     Document Type: Review

References (67)

1. Ehrlich P. Ueber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd. 1909; 5: 273-290.
2. Thomas L. Discussion of cellular and humoral aspects of hypersensitive states. Lawrence HS ed, New York, Hoeber-Harper, 1959.
3. Burnet FM, Cancer. A biological approach. 1. The process of control. Br Med J. 1957; 1: 779-782.
4. Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 1943; 3: 326-333.
5. Foley EJ. Antigenic properties of methylcholanthereneinduced tumors in mice of the strain of origin. Cancer Res. 1953; 13: 835-837.
6. Burnet FM. Immunological surveillance, Oxford, Pergamon Press 1970.
7. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996; 77: 1303-1310.
8. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Ménard S, Pierotti MA, Testori A. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 1991; 49: 44-49.
9. Lipponen PK, Eskelinen MJ, Jauhiainen K, Harju E, Terho R. Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer. 1992; 29A: 69-75.
10. Nacopoulou L, Azaris P, Papacharalampous N, Davaris P. Prognostic significance of histologic host response in cancer of the large bowel. Cancer. 1981; 47: 930-936.
11. Epstein NA, Fatti LP. Prostatic carcinoma: some morphological features affecting prognosis. Cancer. 1976; 37: 2455-2465.
12. Deligdisch L, Jacobs AJ, Cohen CJ. Histologic correlates of virulence in ovarian adenocarcinoma. II. Morphologic correlates of host response. Am J Obstet Gynecol. 1982; 144: 885-889.
13. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol. 1986; 39: 585-589.
14. Palma L, Di Lorenzo N, Guidetti B. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. J Neurosurg 1978; 49: 854-861.
15. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27: 932-943.
16. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010; 127: 759-767.
17. Facciabene A, Motz GT, Coukos G. T regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012; 72: 2162-2171.
18. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996; 183: 725-729.
19. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science. 1974;183: 534-536.
20. Outzen HC, Custer RP, Eaton GJ, Prehn RT. Spontaneous and induced tumor incidence in germfree "nude" mice. J Reticuloendothel Soc. 1975; 17: 1-9.
21. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA. 1998; 95: 7556-7561.
22. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD, IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111.
23. Dighe A, Richards E, Old L, Schreiber R. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-receptors. Immunity. 1994; 1: 447-456.
24. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A.Interferon γ-1b compared with placebo in metastatic renal-cell carcinoma. Canad Urolo Oncology Group. N. Engl. J. Med. 1998; 338: 1265-1271.
25. Wiesenfeld M, O'Connell MJ, Wieand HS, Gonchoroff NJ, Donohue JH, Fitzgibbons RJ Jr., Krook JE, Mailliard JA, Gerstner JB, Pazdur R. Controlled clinical trial of interferon-γ as postoperative surgical adjuvant therapy for colon cancer. J Clin Oncol. 1995; 13:2324-2329.
26. Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, Tschetter LK, Kardinal CG, Twito DI, Levitt R, Gerstner JB. Phase III trial of recombinant interferon ? in complete responders with small-cell lung cancer. J Clin Oncol. 1994; 12: 2321-2326.
27. van den Broek ME, Kägi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Zinkernagel RM, Hengarten H. Decreased tumor surveillance in perforin-deficient mice. J Exp Med. 1996; 184: 1781-1790.
28. Bolitho P, Street SEA, Westwood JA, Edelmann W, MacGregor D, Waring P, Murray WK, Godfrey DI, Trapani JA, Johnstone RW, Smyth MJ. Perforin-mediated suppression of B-cell lymphoma. Proc Natl Acad Sci USA. 2009; 106: 2723-2728.
29. Street SE, Hayakawa Y, Zhan Y, Lew AM, MacGregor D, Jamieson AM, Diefenbach A, Yagita H, Godfrey DI, Smyth MJ. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gamma delta T cells. J Exp Med. 2004;199: 879-884.
30. Clementi R, Locatelli F, Dupré L, Garaventa A, Emmi L, Bregni M, Cefalo G, Moretta A, Danesino C, Comis M, Pession A, Ramenghi U, Maccario R, et al. A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood. 2005; 105: 4424-4428.
31. Melief CJM, Schwartz RS. Immunocompetence and malignancy, In Cancer: A Comprehensive treatise, Vol. 1, Becker FF Ed., New York, Plenum Press, 1975, pp. 121-160.
32. Schulz TF. Cancer and viral infection in immunocompromised individuals. Int J Cancer. 2009; 125: 1755-1763.
33. Gaidano G, Dalla-Favera R. Biologic aspects of human immunodeficiency virus-related lymphoma. Curr Opin Oncol. 1992; 4: 900-906.
34. Ru-Chen M. Epstein-Barr virus, the immune system, and associated diseases. Front Microbiol 2011; 2: 5.
35. Mesri EA, Cesarman E, Arvanitakis L, Rafii S, Moore MA, Posnett DN, Knowles DM, Asch AS. Human herpes virus-8/Kaposi's sarcoma associated herpes virus is a new transmissible virus that infects B cells. J Exp Med 1996; 183: 2385-2390.
36. Tholey DM, Ahn J. Impact of hepatitis C virus infection on hepatocellular carcinoma. Gastroent Clin North Am. 2015; 44: 761-773.
37. Engels EA, Frisch M, Goedert JJ, Biggar RJ, Miller RW. Merkel cell carcinoma and HIV infection. Lancet 2002; 359: 497-498.
38. Mc Farlane GA, Munro A. Helicobacter pylori and gastric cancer. Br J Surg. 1997; 84: 1190-1199.
39. Silva J, Cerqueira F, Medeiros R. Chlamydia trachomatis infection: implications for HPV status and cervical cancer. Arch Gynecol Obstet. 2014; 289: 715-723.
40. Morrissey D, O'Sullivan GC, Tangney M. Tumour targeting with systemically administered bacteria. Curr Gene Ther. 2010; 10: 3-14.
41. Toso JF. Phase I study of the intravenous administration of attenuated Salmonella typhi murium to patients with metastatic melanoma. J Clin Oncol. 2002; 20: 142-152.
42. Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harb Perspect. Med. 2013; 3: a015677.
43. Pawelec G, Derhov E, Larbi A. Immunosenescence and cancer. Crit Rev Oncol Hematol. 2010; 75: 165-172.
44. Fulop T, Kotb R, Fortin CF, Pawelec G, de Angelis F, Larbi A. Potential role of immunosenescence in cancer development. Ann N Y Acad Sci. 2010; 1197: 158-165.
45. Martinez C. Effect of early thymectomy on development of mammary tumours in mice. Nature 1964; 203: 1188.
46. Penn I. Tumors of the immunocompromised patient. Ann Rev Med. 1988; 39: 63-73.
47. Yunis EJ, Martinez C, Smith J, Stutman O, Good RA. Spontaneous mammary adenocarcinoma in mice: influence of thymectomy and reconstitution with thymus grafts or spleen cells. Cancer Res. 1969; 29: 174-178.
48. Stewart T, Tsai SC, Grayson H, Henderson R, Opelz G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet. 1995; 346: 796-798.
49. Stutman O. Immunodepression and malignancy. Adv Cancer Res. 1975; 22: 261-422.
50. Sirvastava PK. Immunity to cancers, in Male D, Brostoff J, Roth DB, Roitss I, eds. Immunology, Seventh edition, Mosby Elsevier, 2006, pp. 422.
51. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3: 991-998.
52. Gasser S, Raulet DH. The DNA damage response arouses the immune system. Cancer Res. 2006; 66: 3959-3962.
53. Dhodapkar MV. Immune response to premalignancy: insights from patients with monoclonal gammopathy. Ann N Y Acad Sci. 2005; 1062: 22-28.
54. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med. 2003; 198: 1753-1757.
55. Corthay A. Does the immune system naturally protect against cancer? Front Immunol. 2014; 12: 197.
56. Teng MW, Galon J, Fridman WH, Smyth MJ. From mice to humans: developments in cancer immunoediting. J Clin Invest. 2015; 125: 3338-3346.
57. Muenst S, Läubli H, Soysal SD, Zippelius A, Tzankov A, Hoeller S. The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med. 2016; 279: 541-562.
58. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Ann Rev Immunol. 2004; 22: 329-360.
59. Schwann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117: 1137-1146.
60. Ledford H. Cancer treatment: the killer within. Nature 2014;505: 24-26.
61. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non Hodgkin's lymphoma. N Engl J Med. 2008; 359: 613-626.
62. Gulley JL, Mulders P, Albers P, Banchereau J, Bolla M, Pantel K, Powles P. Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. Oncoimmunology. 2015; 10: e1107698.
63. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
64. He YF, Zhang GM, Wang XH, Zhang H, Yuan Y, Li D, Feng ZH. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J Immunol. 2004;173: 4919-4928.
65. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004; 64: 1140-1145.
66. Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol 2015; 27: 39-46.
67. Sharma P, Allison JP. The future of immune check point therapy. Science. 2015; 348: 56-61.